In a large study on T2DM patients treated with metformin or insulin, which used an international federated database, a statistically significant decrease in the incidence of gout was observed 5 years after the introduction of SGLT2 inhibitors, but not with GLP-1 mimetics [96]. This evidence concerns the gene SLC5A2 and gout.